Literature DB >> 33563636

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group.

Alexander I Spira1, Mark D Stewart2, Suzanne Jones3, Elaine Chang4, Anitra Fielding5, Nicole Richie6, Laura S Wood7, Michael A Thompson8, Lee Jones9, Abhilasha Nair4, Brandon A Mahal10, David E Gerber11.   

Abstract

PURPOSE: In clinical research, eligibility criteria promote patient safety and optimize the evidence generated from clinical trials. However, overly stringent eligibility criteria, including laboratory requirements, may limit enrollment, resulting in delayed trial completion and potentially limiting applicability of trial results to a general practice population. EXPERIMENTAL
DESIGN: Starting in 2018, a working group consisting of experts in direct patient care, the FDA, industry, and patient advocacy developed recommendations to guide the optimal use of laboratory reference ranges and testing intervals in clinical trial eligibility criteria and study procedures. The working group evaluated current eligibility criteria across different clinical trial phases and performed a literature review to evaluate the impact of and justification for laboratory test eligibility requirements and testing intervals in clinical trials. Recommendations were developed on the basis of the goals of promoting safety and optimizing the evidence generated, while also expanding eligibility and applicability, and minimizing excess burden of trial participation.
RESULTS: In general, we found little variation over time and trial phase in laboratory test requirements, suggesting that these eligibility criteria are not refined according to ongoing clinical experience. We propose recommendations to optimize the use of laboratory tests when considering eligibility criteria.
CONCLUSIONS: Tailoring the use of laboratory test requirements and testing intervals may increase the number and diversity of patients in clinical trials and provide clinical data that more closely represent the general practice populations.See related commentary by Giantonio, p. 2369. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 33563636      PMCID: PMC8102342          DOI: 10.1158/1078-0432.CCR-20-3853

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  28 in total

Review 1.  Eligibility criteria for phase I clinical trials: tight vs loose?

Authors:  Laeeq Malik; David Lu
Journal:  Cancer Chemother Pharmacol       Date:  2019-02-27       Impact factor: 3.333

2.  Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.

Authors:  Sandra Garcia; Ajit Bisen; Jingsheng Yan; Xian-Jin Xie; Suresh Ramalingam; Joan H Schiller; David H Johnson; David E Gerber
Journal:  J Thorac Oncol       Date:  2017-08-09       Impact factor: 15.609

3.  Variability of creatinine measurements in clinical laboratories: results from the CRIC study.

Authors:  Marshall Joffe; Chi-yuan Hsu; Harold I Feldman; Matthew Weir; J R Landis; L Lee Hamm
Journal:  Am J Nephrol       Date:  2010-04-14       Impact factor: 3.754

4.  New Benchmarks Characterizing Growth in Protocol Design Complexity.

Authors:  Kenneth A Getz; Rafael A Campo
Journal:  Ther Innov Regul Sci       Date:  2017-06-23       Impact factor: 1.778

5.  Platelet counts differ by sex, ethnicity, and age in the United States.

Authors:  Jodi B Segal; Alison R Moliterno
Journal:  Ann Epidemiol       Date:  2005-10-24       Impact factor: 3.797

6.  A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Authors:  Sawsan Rashdan; David E Gerber
Journal:  Transl Cancer Res       Date:  2017-02       Impact factor: 1.241

7.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

Authors:  Nancy U Lin; Tatiana Prowell; Antoinette R Tan; Marina Kozak; Oliver Rosen; Laleh Amiri-Kordestani; Julia White; Joohee Sul; Louise Perkins; Katherine Beal; Richard Gaynor; Edward S Kim
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

8.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.

Authors:  Stuart M Lichtman; R Donald Harvey; Marie-Anne Damiette Smit; Atiqur Rahman; Michael A Thompson; Nancy Roach; Caroline Schenkel; Suanna S Bruinooge; Patricia Cortazar; Dana Walker; Louis Fehrenbacher
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

9.  Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Authors:  Edward S Kim; Suanna S Bruinooge; Samantha Roberts; Gwynn Ison; Nancy U Lin; Lia Gore; Thomas S Uldrick; Stuart M Lichtman; Nancy Roach; Julia A Beaver; Rajeshwari Sridhara; Paul J Hesketh; Andrea M Denicoff; Elizabeth Garrett-Mayer; Eric Rubin; Pratik Multani; Tatiana M Prowell; Caroline Schenkel; Marina Kozak; Jeff Allen; Ellen Sigal; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

10.  Rethinking the therapeutic misconception: social justice, patient advocacy, and cancer clinical trial recruitment in the US safety net.

Authors:  Nancy J Burke
Journal:  BMC Med Ethics       Date:  2014-09-20       Impact factor: 2.652

View more
  2 in total

1.  ELaPro, a LOINC-mapped core dataset for top laboratory procedures of eligibility screening for clinical trials.

Authors:  Ahmed Rafee; Sarah Riepenhausen; Philipp Neuhaus; Alexandra Meidt; Martin Dugas; Julian Varghese
Journal:  BMC Med Res Methodol       Date:  2022-05-14       Impact factor: 4.612

2.  Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials.

Authors:  Owen Garrick; Ruben Mesa; Andrea Ferris; Edward S Kim; Edith Mitchell; Otis W Brawley; John Carpten; Keith D Carter; Joseph Coney; Robert Winn; Stephanie Monroe; Fabian Sandoval; Edith Perez; Mitzi Williams; Evan Grove; Quita Highsmith; Nicole Richie; Susan M Begelman; Asha S Collins; Jamie Freedman; Melissa S Gonzales; Gerren Wilson
Journal:  Ethn Dis       Date:  2022-01-20       Impact factor: 2.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.